Cryoneurolysis for Spasticity Treatment: Long-term Clinical Outcomes and Mechanisms in the Central Nervous System

NANot yet recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

December 1, 2027

Study Completion Date

May 1, 2028

Conditions
Spasticity as Sequela of Stroke
Interventions
DEVICE

Cryoneurolysis

Each participant will receive cryoneurolysis which involves the application of extreme cold directly to, or near targeted nerves under ultrasound guidance. This cold causes axonotmesis to occur, thereby completely preventing the treated nerve from propagating any signal. Cryoneurolysis produces an effect called Wallerian degeneration, where the treated nerve's axon is destroyed but the epineurium and perineurium are left intact. Therefore, the axon can regenerate, following the same path as prior to treatment.

Trial Locations (1)

N6C 0A7

Parkwood Institute, London

Sponsors
All Listed Sponsors
collaborator

Pacira Pharmaceuticals, Inc

INDUSTRY

lead

Sue Peters

OTHER

NCT06958289 - Cryoneurolysis for Spasticity Treatment: Long-term Clinical Outcomes and Mechanisms in the Central Nervous System | Biotech Hunter | Biotech Hunter